• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    CohBar Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement

    11/1/23 9:05:22 AM ET
    $CWBR
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CWBR alert in real time by email
    0001522602 false 0001522602 2023-11-01 2023-11-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

     

    November 1, 2023

    Date of Report

    (Date of earliest event reported)

     

     

     

    COHBAR, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   001-38326   26-1299952

    (State or other jurisdiction

    of incorporation)

     

    (Commission File Number)

     

    (IRS Employer

    Identification No.)

     

    1455 Adams Drive, Suite 1308

    Menlo Park, CA 94025

    (Address of principal executive offices, including Zip Code)

     

    (650) 446-7888

    (Registrant’s telephone number, including area code)

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.001 per share   CWBR   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.02 Termination of a Material Definitive Agreement.

     

    As previously disclosed, on May 22, 2023, CohBar, Inc., a Delaware corporation (“CohBar”), Morphogenesis, Inc., a Delaware corporation (“Morphogenesis”), and Chimera MergeCo, Inc., a Delaware corporation and wholly owned subsidiary of CohBar (“Merger Sub”), entered into an Agreement and Plan of Merger (as amended by the First Amendment thereto dated as of August 28, 2023, the “Merger Agreement”), which provided that, among other things, and subject to the satisfaction or waiver of certain conditions set forth in the Merger Agreement, Merger Sub would merge with and into Morphogenesis, with Morphogenesis surviving as a wholly owned subsidiary of CohBar (the “Merger”). The Merger Agreement is filed as Annex A to CohBar’s definitive proxy statement/prospectus filed with the Securities and Exchange Commission on September 12, 2023 (the “Proxy Statement/Prospectus”). The material terms of the Merger Agreement were described in the section titled “The Merger Agreement” of the Proxy Statement/Prospectus and are incorporated by reference herein.

     

    In connection with the Merger Agreement, CohBar filed an initial listing application for the common stock of the combined company to be listed on The Nasdaq Capital Market (“Nasdaq”). It is a condition of the closing of the Merger under the Merger Agreement that the initial listing application with Nasdaq shall have been approved by Nasdaq. On October 30, 2023, CohBar and Morphogenesis received oral guidance from Nasdaq on the initial listing application indicating that the structure proposed by the parties would not receive approval. As a result, CohBar and Morphogenesis proceeded to discuss the oral guidance from Nasdaq over the course of October 30 and 31, 2023. As of October 31, 2023, CohBar had not received approval of the initial listing application from Nasdaq.

     

    On October 31, 2023, the board of directors of CohBar, in consultation with management and after careful consideration, determined that there was not a viable path forward to consummate the Merger primarily due to the oral guidance received from Nasdaq. On November 1, 2023, CohBar received a termination notice from Morphogenesis pursuant to Section 8.1(b) of the Merger Agreement, effective November 1, 2023, and the Merger Agreement was terminated in accordance with its terms. Section 8.1(b) of the Merger Agreement provides that the Merger Agreement may be terminated by CohBar or Morphogenesis if the Merger has not been consummated by October 31, 2023.

     

    CohBar intends to commence the process of liquidating and dissolving itself in accordance with its organizational documents and applicable law. As of September 30, 2023, CohBar had cash, cash equivalents and investments of approximately $9.1 million (unaudited) and accrued liabilities of approximately $1.5 million (unaudited). Due to anticipated but as yet unquantifiable expenses associated with the liquidation and dissolution process, an estimate of the amounts expected to be available to return to CohBar’s public stockholders, if any, cannot be provided at this time.

     

    Forward-Looking Statements

     

    This Current Report on Form 8-K contains forward-looking statements that are not historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based only on CohBar’s current beliefs, expectations and assumptions regarding the future of CohBar’s business, future plans and strategies, projections, anticipated events and other future conditions. In some cases you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely” or the negative or plural of these words or similar expressions. Examples of forward-looking statements contained in this Current Report on Form 8-K include statements concerning our intention to commence the process of liquidating and dissolving, our anticipated but as yet unquantifiable expenses associated with the liquidation and dissolution process and our inability to provide an estimate of the amounts expected to be available to return to CohBar’s public stockholders, if any. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include: risks associated with our ability to commence the liquidation and dissolution of CohBar, risks related to our ability to correctly estimate expenses associated with the termination of the Merger Agreement or the liquidation and dissolution of CohBar, unexpected costs, charges or expenses resulting from the termination of the Merger Agreement or the liquidation and dissolution of CohBar, as well as uncertainties regarding the impact any delay in the liquidation and dissolution process would have on the cash resources of CohBar and other events and unanticipated spending and costs that could reduce CohBar’s cash resources, risks associated with any potential litigation resulting from the termination of the Merger Agreement or the liquidation and dissolution of CohBar and additional risks described in the “Risk Factors” section of CohBar’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023 and the Proxy Statement/Prospectus. Additional assumptions, risks and uncertainties are described in detail in CohBar’s registration statements, reports and other filings with the SEC and applicable Canadian authorities, which are available on CohBar’s website, and at www.sec.gov or www.sedar.com.

     

    You are cautioned that such statements are not guarantees of future performance and that CohBar’s actual results may differ materially from those set forth in the forward-looking statements. The forward-looking statements and other information contained in this Current Report on Form 8-K are made as of the date hereof and CohBar does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy any securities.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      COHBAR, INC.
         
    Date: November 1, 2023 By: /s/ Jeffrey F. Biunno
      Name: Jeffrey F. Biunno
      Title: Chief Financial Officer

     

     

    2

     

    Get the next $CWBR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CWBR

    DatePrice TargetRatingAnalyst
    8/11/2021$5.00Speculative Buy → Buy
    WBB Securities
    More analyst ratings

    $CWBR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CohBar, Inc.: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (Form 8-K)

      Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2023, CohBar, Inc. (the "Company") was notified by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a "public shell," and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing requirements under Nasdaq Listing Rule 5605 and certain of Nasdaq's filing requirements under Nasdaq Listing Rule 5250(c)(1)

      11/27/23 6:05:00 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Reports Second Quarter 2023 Financial Results

      MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. ("Morphogenesis"), for an all-stock transaction to advance a late-stage oncology pipeline. The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on The Nasdaq Capital Market ("Nasdaq"). The transaction is exp

      8/14/23 4:01:05 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Morphogenesis, Inc. and CohBar, Inc. Announce Positive Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)

      IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores IFx-Hu2.0 mechanism; Demonstrates activation of systemic tumor-specific immune responses Data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fa. and MENLO PARK, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology compa

      6/5/23 8:05:22 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

      SC 13G/A - CohBar, Inc. (0001522602) (Subject)

      2/8/23 9:00:30 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

      SC 13G/A - CohBar, Inc. (0001522602) (Subject)

      2/8/23 9:00:30 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by CohBar Inc. (Amendment)

      SC 13G/A - CohBar, Inc. (0001522602) (Subject)

      2/14/22 3:31:32 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CohBar upgraded by WBB Securities with a new price target

      WBB Securities upgraded CohBar from Speculative Buy to Buy and set a new price target of $5.00

      8/11/21 7:20:55 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Maxim Group initiated coverage on CohBar with a new price target

      Maxim Group initiated coverage of CohBar with a rating of Buy and set a new price target of $3.00

      4/23/21 9:00:48 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Aegis Capital initiated coverage on CohBar with a new price target

      Aegis Capital initiated coverage of CohBar with a rating of Buy and set a new price target of $6.00

      3/15/21 11:37:59 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    SEC Filings

    See more
    • SEC Form 25-NSE filed by CohBar Inc.

      25-NSE - CohBar, Inc. (0001522602) (Subject)

      12/27/23 9:01:40 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - CohBar, Inc. (0001522602) (Filer)

      11/27/23 5:21:26 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Inc. filed SEC Form 8-K: Leadership Update, Other Events

      8-K - CohBar, Inc. (0001522602) (Filer)

      11/13/23 9:01:36 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Leadership Updates

    Live Leadership Updates

    See more
    • CohBar Appoints Effie Tozzo, Ph.D. to Its Board of Directors

      MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company's Board, effective July 11, 2022. Dr. Tozzo brings extensive research and development experience at both established pharmaceutical and innovative biotechnology companies. "We are delighted to add Dr. Tozzo to our Board and will tap into her considerable expertise in advancing preclinical assets to the clini

      7/12/22 9:00:00 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Announces Changes to its Board of Directors and R&D Leadership

      Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced changes to its Board of Directors, Scientific Advisory Board (SAB), and R&D leadership. CohBar's founders Drs. Nir Barzilai, Pinchas Cohen, and John Amatruda have transitioned from the company's Board of Directors to a reconstituted SAB. The SAB will be comprised of experts in mitochondrial science and other dis

      12/17/21 9:00:00 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Appoints Joanne Yun, Ph.D. to Its Board of Directors

      MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joanne Yun, Ph.D. as an independent director on the company's Board, effective September 14, 2021. Dr. Yun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry. "We are very pleased to add Dr. Yun as an independent director and look forward to her strategic input as we continue to develop our diverse pipeline of novel mitochondria based therapeutics," said David Greenwood, Chair

      9/15/21 9:00:00 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Sarret Joseph J. was granted 131,017 shares, increasing direct ownership by 655% to 151,017 units

      4 - CohBar, Inc. (0001522602) (Issuer)

      8/3/22 9:00:22 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4: Biunno Jeffrey Francis was granted 26,203 shares, increasing direct ownership by 84% to 57,355 units

      4 - CohBar, Inc. (0001522602) (Issuer)

      8/3/22 9:00:26 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Tozzo Stephanie

      4 - CohBar, Inc. (0001522602) (Issuer)

      7/12/22 4:06:36 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CWBR
    Financials

    Live finance-specific insights

    See more
    • Lifshitz Law PLLC Announces Investigations of CWBR, GHL, PDCE, and VECT

      NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-

      6/3/23 8:17:00 PM ET
      $CWBR
      $GHL
      $PDCE
      $VECT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Investment Bankers/Brokers/Service
      Finance
    • CohBar, Inc. and Morphogenesis, Inc. Enter into Definitive Merger Agreement to Advance an Innovative Late-stage Clinical Immuno-oncology Pipeline of Therapies to Overcome Resistance to Cancer Immunotherapy

      Combined company will operate under the name "TuHURA Biosciences, Inc." and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and webcast today, Tuesday, May 23rd at 8:30 AM ET MENLO PARK, Calif. and TAMPA, Fla. , May 23, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) ("CohBar" or the "company") and Morphogenesis, Inc. ("M

      5/23/23 7:30:39 AM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • CohBar Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

      MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. "I'm pleased with the team's performance during the third quarter of 2022 in advancing our top priorities, including improving the formulation of CB5138-3, our product candidate for IPF," stated Dr. Joseph Sarret, Chief Executive Officer. "We continue to operate the company i

      11/8/22 4:03:07 PM ET
      $CWBR
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care